Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Sunesis Pharmaceuticals, Inc is a biotechnology business based in the US. Sunesis Pharmaceuticals shares (SNSS) are listed on the NASDAQ and all prices are listed in US Dollars. Sunesis Pharmaceuticals employs 24 staff and has a trailing 12-month revenue of around USD$2.2 million.
|Latest market close||USD$1.78|
|52-week range||USD$1.12 - USD$11.3|
|50-day moving average||USD$1.3211|
|200-day moving average||USD$2.5247|
|Wall St. target price||USD$3.25|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.48|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-12)||N/A|
|1 month (2020-12-23)||-7.29%|
|3 months (2020-10-19)||N/A|
|6 months (2020-07-19)||N/A|
|1 year (2020-01-19)||N/A|
|2 years (2019-01-19)||N/A|
|3 years (2018-01-19)||N/A|
|5 years (2016-01-19)||N/A|
|Revenue TTM||USD$2.2 million|
|Gross profit TTM||USD$2.1 million|
|Return on assets TTM||-39.43%|
|Return on equity TTM||-77.84%|
|Market capitalisation||USD$31.1 million|
TTM: trailing 12 months
There are currently 607,795 Sunesis Pharmaceuticals shares held short by investors – that's known as Sunesis Pharmaceuticals's "short interest". This figure is 3% up from 589,885 last month.
There are a few different ways that this level of interest in shorting Sunesis Pharmaceuticals shares can be evaluated.
Sunesis Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Sunesis Pharmaceuticals shares currently shorted divided by the average quantity of Sunesis Pharmaceuticals shares traded daily (recently around 568032.71028037). Sunesis Pharmaceuticals's SIR currently stands at 1.07. In other words for every 100,000 Sunesis Pharmaceuticals shares traded daily on the market, roughly 1070 shares are currently held short.
However Sunesis Pharmaceuticals's short interest can also be evaluated against the total number of Sunesis Pharmaceuticals shares, or, against the total number of tradable Sunesis Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sunesis Pharmaceuticals's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Sunesis Pharmaceuticals shares in existence, roughly 30 shares are currently held short) or 0.0346% of the tradable shares (for every 100,000 tradable Sunesis Pharmaceuticals shares, roughly 35 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Sunesis Pharmaceuticals.
Find out more about how you can short Sunesis Pharmaceuticals stock.
We're not expecting Sunesis Pharmaceuticals to pay a dividend over the next 12 months.
Sunesis Pharmaceuticals's shares were split on a 1:10 basis on 3 September 2020. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Sunesis Pharmaceuticals shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Sunesis Pharmaceuticals shares which in turn could have impacted Sunesis Pharmaceuticals's share price.
Over the last 12 months, Sunesis Pharmaceuticals's shares have ranged in value from as little as $1.12 up to $11.3. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sunesis Pharmaceuticals's is 1.9143. This would suggest that Sunesis Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of hematologic and solid cancers. Its lead product candidate is vecabrutinib, a non-covalent inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and other B-cell malignancies. The company is also developing SNS-510, which is in preclinical pharmacology studies for the treatment of solid tumor and hematologic malignancies; various other partnered programs, such as TAK-580, a pan-Raf inhibitor program that is in Phase 1 clinical trial for the treatment of pediatric low-grade glioma; and vosaroxin, an anti-cancer quinolone derivative that intercalates DNA and inhibits topoisomerase II. It has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of PDK1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
Steps to owning and managing SSNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMBC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMED, with 24-hour and historical pricing before you buy.
Steps to owning and managing SJW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFBS, with 24-hour and historical pricing before you buy.
Steps to owning and managing LEDS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SC, with 24-hour and historical pricing before you buy.
Steps to owning and managing RTW, with 24-hour and historical pricing before you buy.
Steps to owning and managing RIVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing RVSB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.